October 2020

First-in-Human Trial Completed for a Novel Treatment for Osteoporosis

Haoma Medica, London, England, announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis. The first-in-human trial initiated last year in healthy adults studied single and multiple doses of the drug. The primary objective was to assess the safety, tolerability, and pharmacokinetics.

“There were no significant safety or tolerability concerns up to the highest doses tested which underlines our expectation that NaQuinate is safe and well tolerated,” said Dr. Cenk Oguz, Haoma Medica’s chief medical officer.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.